$19.0M
Cross-Border Impact Ventures led the round, which will fund international expansion and product development.
"We’re still diagnosing in the twenty-first century with a test invented in the 1800s, and one that needs specialist equipment and training most of the world doesn’t have access to. Lower-income and minority communities pay the price for that first. That’s the gap we want to close at TidalSense, and the NHS is the first place we’re doing it,"
